Far Eastern Memorial Hospital

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

4 drugs in development

Approved4

Phase 33

Phase 22

Preclinical3

By Therapeutic Area

top 4

Musculoskeletal

222%

Nephrology

111%

Neurology

111%

Oncology

111%

R&D Momentum

44/100

Pipeline Velocity

19/100

Trial Completion Rate

83/100

Pipeline Concentration

28/100

Pipeline Freshness

0/100

Strategic Signals

↗Active in Nephrology but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Jul 14, 2026

Completed

Evaluating Mental Health Crisis Training Outcomes Among Police, Firefighters, and Public Health Staff

Jul 11, 2026

Completed

Evaluation of CPR Training and Agonal Breathing Recognition Among New Taipei City Police Officers in Out-of-Hospital Cardiac Arrest Events

Earlier

Jun 26, 2026TrialTactile Feedback on Pelvic Floor Muscle Training in the 3rd Trimester of Pregnancy to Prevent of Stress Urinary Incontinence and Its Influence on Biological and Psychological Symptoms

Jun 25, 2026TrialEffects of Single-Session Facial Acupuncture on Dermal Structure and Aesthetic Satisfaction: A Randomized Controlled Trial Combining High-Frequency Ultrasound and Patient-Reported Outcomes

Jun 25, 2026TrialComparison of the Safety and Efficacy of the Far Eastern Memorial Hospital Electronic Glucose Management System (eGMS) With Conventional Subcutaneous Basal-Bolus Insulin Protocol in Ordinary Ward Patients: A Prospective Randomized Controlled Trial

Aug 7, 2025TrialThe Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Function, and Lower Urinary Tract Blood Flow Perfusion in Women With Overactive Bladder Syndrome: Randomized Controlled Trial

Aug 15, 2024TrialIntraperitoneal Chemotherapy in Recurrent Ovarian Cancer

Sep 12, 2023TrialComparisons of the Impact of Monotherapy With Mirabegron or Tolterodine Versus Combined Treatment With Mirabegron and Tolterodine on Autonomic Function and Bladder Blow Flow in Women With Overactive Bladder Syndrome: a Randomized Controlled Study

4 more events

Apr 18, 2023TrialTherapeutic Efficacy in Women With Stress Urinary Incontinence

Feb 25, 2023TrialComparisons of the Therapeutic Effects of Dienogest and Danazol on Endometriosis

Jun 6, 2022TrialIntraperitoneal Chemotherapy Versus Triweekly Chemotherapy

Feb 7, 2022TrialHRT on Overactive Bladder Symptoms, Sexual Function, Depressive Symptoms, Autonomic Function, and Arterial Stiffness

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

LivialPhase 2

Low Back Pain

Detrol LaPhase 3

Osteoporosis

LivialPhase 3

Nephrology

Nephrolithiasis

Detrol LaApproved

Neurology

Neuropathic Pain

Detrol LaApproved

Oncology

Breast Cancer

LivialPhase 3

Unknown / Other

Cognition

Oxybutynin ERApproved

Lower Urinary Tract Symptom

Estradiol & medroxyprogesterone acetateApproved

LivialApproved

Detrol LaApproved

Overactive Bladder

Detrol LaApproved

Oxybutynin ERPhase 3

Pelvic Organ Prolapse

Detrol LaPhase 3

Polyuria

Detrol LaApproved

Sleep Disorder

LivialApproved

Showing 15 of 20 programs

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)